Alvaro Molina-Morales

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Celyvir: Oncolytic Virotherapy with Mesenchymal Stromal Cells. From Concept to Clinical Translation.

Celyvir: Oncolytic Virotherapy with Mesenchymal Stromal Cells. From Concept to Clinical Translation.

Journal: Human gene therapy

Published: July 16, 2026

Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy.

Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy.

Journal: Experimental hematology & oncology

Published: January 14, 2026

Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy.

Deletion of the RGD motif from the penton base in oncolytic adenoviruses enhances antitumor efficacy of combined CAR T cell therapy.

Journal: Molecular therapy. Oncology

Published: April 18, 2024

Switchable CAR T cell strategy against osteosarcoma.

Switchable CAR T cell strategy against osteosarcoma.

Journal: Cancer immunology, immunotherapy : CII

Published: October 11, 2022

Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing.

Toll-like Receptor Signaling-deficient Cells Enhance Antitumor Activity of Cell-based Immunotherapy by Increasing Tumor Homing.

Journal: Cancer research communications

Published: September 13, 2022

Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment.

Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment.

Journal: Frontiers in cell and developmental biology

Published: December 14, 2021

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.

Journal: Journal for immunotherapy of cancer

Published: December 26, 2020

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models.

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models.

Journal: Cancers

Published: June 12, 2020

SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications.

SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications.

Journal: Cancers

Published: February 14, 2020

AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.

AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.

Journal: Cancer gene therapy

Published: January 10, 2020

Sarcoma treatment in the era of molecular medicine.

Sarcoma treatment in the era of molecular medicine.

Journal: EMBO molecular medicine

Published: July 09, 2019

Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.

Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.

Journal: Molecular cancer therapeutics

Published: April 27, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026